According to previous studies, SGLT2 inhibitors have the potential to provide renal and cardioprotective benefits to patients with T1DM through the reduction of blood glucose levels with low hypoglycaemia risk, glomerular hyperfiltration, blood pressure, volume overload and weight (Bonaventura et al., 2019; Kario et al., 2018; Nespoux & Vallon, 2018; Vallon et al., 2013). The gene discussed is SLC5A2; the disease is type 1 diabetes mellitus.